Search Results - "De Petris, Luigi"

Refine Results
  1. 1
  2. 2
  3. 3

    Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC by Kilvaer, Thomas Karsten, Rakaee, Mehrdad, Hellevik, Turid, Vik, Jørg, Petris, Luigi De, Donnem, Tom, Strell, Carina, Ostman, Arne, Busund, Lill-Tove Rasmussen, Martinez-Zubiaurre, Inigo

    Published in Scientific reports (15-07-2019)
    “…Preclinical evidence suggests that stromal expression of platelet-derived growth factor receptors (PDGFRs) stimulates tumor development and diminishes…”
    Get full text
    Journal Article
  4. 4

    Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study by Marzano, Luca, Darwich, Adam S., Dan, Asaf, Tendler, Salomon, Lewensohn, Rolf, De Petris, Luigi, Raghothama, Jayanth, Meijer, Sebastiaan

    Published in Clinical and translational science (01-08-2024)
    “…The potential of real‐world data to inform clinical trial design and supplement control arms has gained much interest in recent years. The most common approach…”
    Get full text
    Journal Article
  5. 5

    Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies by Rounis, Konstantinos, Makrakis, Dimitrios, Gioulbasanis, Ioannis, Ekman, Simon, De Petris, Luigi, Mavroudis, Dimitris, Agelaki, Sofia

    Published in Life (Basel, Switzerland) (12-06-2022)
    “…Cancer cachexia syndrome (CCS) is a multifactorial metabolic syndrome affecting a significant proportion of patients. CCS is characterized by progressive…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8

    The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy by Tendler, Salomon, Kanter, Lena, Lewensohn, Rolf, Ortiz-Villalón, Cristian, Viktorsson, Kristina, De Petris, Luigi

    Published in PloS one (26-10-2020)
    “…The aim was to analyse the tumor expression of Notch1, Hes1, Ascl1, and DLL3 in Small-Cell Lung Cancer (SCLC) and each such biomarker's potential association…”
    Get full text
    Journal Article
  9. 9
  10. 10

    PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer by Dan, Asaf, Aricak, Ozan, Rounis, Konstantinos, Montero-Fernandez, M Angeles, Guijarro, Ricardo, Ekman, Simon, Ortiz-Villalón, Cristian, De Petris, Luigi

    Published in Frontiers in oncology (26-09-2024)
    “…Programmed death ligand - 1 (PD-L1) expression is a well-established predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). Programmed…”
    Get full text
    Journal Article
  11. 11

    Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting by Skribek, Marcus, Rounis, Konstantinos, Makrakis, Dimitrios, Agelaki, Sofia, Mavroudis, Dimitris, De Petris, Luigi, Ekman, Simon, Tsakonas, Georgios

    Published in Cancers (10-12-2020)
    “…There is lack of data addressing the intracranial (IC) efficacy of immune checkpoint inhibitors (ICIs) on brain metastases (BM) in non-small cell lung cancer…”
    Get full text
    Journal Article
  12. 12

    A novel analytical framework for risk stratification of real‐world data using machine learning: A small cell lung cancer study by Marzano, Luca, Darwich, Adam S., Tendler, Salomon, Dan, Asaf, Lewensohn, Rolf, De Petris, Luigi, Raghothama, Jayanth, Meijer, Sebastiaan

    Published in Clinical and translational science (01-10-2022)
    “…In recent studies, small cell lung cancer (SCLC) treatment guidelines based on Veterans’ Administration Lung Study Group limited/extensive disease staging and…”
    Get full text
    Journal Article
  13. 13

    The role of p53 in treatment responses of lung cancer by Viktorsson, Kristina, De Petris, Luigi, Lewensohn, Rolf

    “…Resistance to radio- and chemotherapy is a major problem in treatment responses of lung cancer. In this disease, biological markers, that can be predictive of…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer by Efazat, Ghazal, Novak, Metka, Kaminskyy, Vitaliy O, De Petris, Luigi, Kanter, Lena, Juntti, Therese, Bergman, Per, Zhivotovsky, Boris, Lewensohn, Rolf, Hååg, Petra, Viktorsson, Kristina

    Published in Oncotarget (13-09-2016)
    “…Ephrin receptors (Ephs) are reported to control metastatic signaling of non-small cell lung cancer (NSCLC) and other tumors. Here we show for the first time…”
    Get full text
    Journal Article